Published in

Centers for Disease Control and Prevention, Emerging Infectious Diseases, 9(18), p. 1453-1460, 2012

DOI: 10.3201/eid1809.111515

Links

Tools

Export citation

Search in Google Scholar

Control of Fluoroquinolone Resistance through Successful Regulation, Australia

Journal article published in 2012 by Allen C. Cheng ORCID, John Turnidge, Peter Collignon, David Looke, Mary Barton, Thomas Gottlieb
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Fluoroquinolone antimicrobial drugs are highly bioavailable, broad-spectrum agents with activity against gram-negative pathogens, especially those resistant to other classes of antimicrobial drugs. Australia has restricted the use of quinolones in humans through its national pharmaceutical subsidy scheme; and, through regulation, has not permitted the use of quinolones in food-producing animals. As a consequence, resistance to fluoroquinolones in the community has been slow to emerge and has remained at low levels in key pathogens, such as Escherichia coli. In contrast to policies in most other countries, this policy has successfully preserved the utility of this class of antimicrobial drugs for treatment of most infections.